Paratek Pharmaceuticals Inc (PRTK) Analysts See $-0.93 EPS

October 13, 2017 - By Darrin Black

 Paratek Pharmaceuticals Inc (PRTK) Analysts See $ 0.93 EPS
Investors sentiment decreased to 1.89 in 2017 Q2. Its down 0.15, from 2.04 in 2017Q1. It worsened, as 13 investors sold Paratek Pharmaceuticals Inc shares while 23 reduced holdings. 28 funds opened positions while 40 raised stakes. 19.26 million shares or 15.88% more from 16.62 million shares in 2017Q1 were reported.
Suffolk Cap Mngmt Ltd Liability Co reported 0.17% in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). Bnp Paribas Arbitrage stated it has 0% of its portfolio in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). Birchview Cap Lp accumulated 30,150 shares. Paloma Prtn, Connecticut-based fund reported 35,983 shares. Boston Prtn holds 0% or 133,682 shares in its portfolio. The Nebraska-based Ameritas Ptnrs Inc has invested 0% in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). Brown Brothers Harriman accumulated 367,902 shares. 10,168 are held by Bancorporation Of America Corp De. Proshare Advsr Ltd reported 16,191 shares. Goldman Sachs Grp Inc Inc holds 0% or 131,723 shares in its portfolio. One Trading Lp stated it has 295 shares. Fmr Limited Com owns 1.46M shares for 0% of their portfolio. Renaissance Technologies Llc has invested 0.02% in Paratek Pharmaceuticals Inc (NASDAQ:PRTK). Baupost Grp Limited Liability Company Ma stated it has 2.39M shares. Millennium Mngmt Ltd Liability Company holds 21,209 shares or 0% of its portfolio.

Analysts await Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to report earnings on November, 1. They expect $-0.93 earnings per share, up 10.58 % or $0.11 from last year’s $-1.04 per share. After $-0.64 actual earnings per share reported by Paratek Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 45.31 % negative EPS growth. It closed at $24.4 lastly. It is down 62.03% since October 13, 2016 and is uptrending. It has outperformed by 45.33% the S&P500.

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Ratings Coverage

Among 9 analysts covering Paratek Pharmaceuticals (NASDAQ:PRTK), 8 have Buy rating, 0 Sell and 1 Hold. Therefore 89% are positive. Paratek Pharmaceuticals had 21 analyst reports since July 23, 2015 according to SRatingsIntel. On Tuesday, July 18 the stock rating was maintained by Leerink Swann with “Buy”. Robert W. Baird initiated Paratek Pharmaceuticals Inc (NASDAQ:PRTK) rating on Friday, May 13. Robert W. Baird has “Outperform” rating and $30 target. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) has “Hold” rating given on Wednesday, September 2 by Zacks. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) has “Buy” rating given on Thursday, July 23 by Gabelli. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) has “Outperform” rating given on Thursday, October 27 by Leerink Swann. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) has “Buy” rating given on Thursday, June 29 by Cantor Fitzgerald. The rating was maintained by Ladenburg Thalmann with “Buy” on Friday, June 17. As per Wednesday, June 21, the company rating was maintained by Cantor Fitzgerald. The stock of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) earned “Buy” rating by Cantor Fitzgerald on Monday, July 17. On Friday, June 17 the stock rating was maintained by H.C. Wainwright with “Buy”.

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $677.37 million. The Firm is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. It currently has negative earnings. The Company’s product candidates are the antibacterials omadacycline and sarecycline.

More notable recent Paratek Pharmaceuticals Inc (NASDAQ:PRTK) news were published by: which released: “Paratek Puts Skin In The Infection Game” on July 24, 2017, also with their article: “Paratek Pharmaceuticals, Inc. to Host Investor Day on October 17, 2017” published on September 19, 2017, published: “Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017” on September 25, 2017. More interesting news about Paratek Pharmaceuticals Inc (NASDAQ:PRTK) were released by: and their article: “Paratek Pharmaceuticals: The 1 Antibiotic Stock To Buy Now” published on May 22, 2017 as well as‘s news article titled: “Paratek’s omadacycline granted additional QIDP status in US” with publication date: September 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.